PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Pediatr Blood Cancer. Author manuscript; available in PMC 2011 August 1.
Published in final edited form as:
PMCID: PMC2913300
NIHMSID: NIHMS218637

Cyclic Neutropenia and Severe Congenital Neutropenia in Patients with a Shared ELANE Mutation and Paternal Haplotype: Evidence for Phenotype Determination by Modifying Genes

Abstract

Background

Cyclic neutropenia (CN) and severe congenital neutropenia (SCN) are disorders of neutrophil production that differ markedly in disease severity. Mutations of the ELANE gene (the symbol recently replacing ELA2) are considered largely responsible for most cases of CN and SCN, but specific mutations are typically associated with one or the other

Procedure

We performed ELANE genotyping on all individuals and paternal sperm in an SCN kindred with 8 SCN progeny of a sperm donor and 6 different mothers.

Results

One patient with CN had the same S97L ELANE mutation as seven patients with the SCN phenotype. The mutant allele was detected in the donor’s spermatozoa, representing 18% of the ELANE gene pool, but not in DNA from his lymphocytes, neutrophils, or buccal mucosa, indicating gonadal mosaicism.

Conclusions

The coexistence of CN and SCN phenotypes in this kindred with a shared paternal haplotype strongly suggests both a role for modifying genes in determination of congenital neutropenia disease phenotypes, and the classification of CN and SCN within a spectrum of phenotypes expressing varying degrees of the same disease process.

Keywords: cyclic neutropenia, ELANE mutation, severe congenital neutropenia, sperm donor

INTRODUCTION

Cyclic neutropenia (CN) is an autosomal dominant disorder (sporadic or inherited) characterized by regular oscillations of peripheral blood neutrophils from near normal to severely low levels, generally with 21-day periodicity. Absolute neutrophil count (ANC) nadirs are often below 200/mm3 and are associated with fever, mouth ulcers, pharyngitis, sinusitis, or more serious infections (such as colitis with gram negative sepsis).[13] CN usually presents early in childhood but may run an asymptomatic course. Transformation to myelodysplastic syndrome and acute myeloid leukemia has not been reported.[4, 5] Symptomatic CN is responsive to granulocyte colony stimulating factor (G-CSF; filgrastim), often at low doses, which typically shortens nadir duration and increases mean and nadir ANC but usually does not ablate cycling.[6, 7]

Severe congenital neutropenia (SCN) is a phenotypically distinct and usually more severe disease. It is characterized by recurrent, severe infections developing in the first months of life, with ANC’s consistently below 200/mm3. Bone marrow examination characteristically shows maturation arrest of neutrophil precursors at the promyelocyte/myelocyte stage of development.[3, 8] Unlike CN, SCN is characterized by transformation to myelodysplasia and acute myeloid leukemia.[9, 10] Genetic transmission may be either autosomal dominant and recessive, with many more sporadic than inherited cases reported.[1114]

CN and SCN appear to derive largely from heterozygous germline mutations in the ELANE (ELAstase – Neutrophil Expressed) gene, previously termed ELA2. Mutations have been found in 80–100 percent of CN cases [1416] and in 35–63% of SCN cases [3, 16, 17], whether sporadic or inherited. The ELANE gene encodes neutrophil elastase, a chymotryptic serine esterase synthesized during the myeloblast to promyelocyte transition.[18] The mutant elastase likely induces accelerated apoptosis in differentiating myeloid cells.[10, 19, 20] One proposed model suggests that this accelerated apoptosis is due to the production of misfolded elastase proteins and subsequent activation of the unfolded protein response (UPR).[20, 21] However, further studies are needed to define the role of the ELANE gene and its protein product in CN and SCN pathogenesis.

While SCN and CN both appear to largely derive from ELANE mutations, studies have demonstrated that the type of ELANE mutation largely differs between these diseases. Specific mutations have been associated with both CN and SCN in unrelated patients,[21] but the vast majority of mutations are associated with either CN or SCN, not both. SCN and CN-associated mutations tend to vary in genetic location and possibly, effect on elastase activity. For example, a mutation mapping study of 81 unrelated patients with SCN (n=54) or CN (n=27) found that CN ELANE mutations tend to be located in exons 2,3, and 4 (which encode the mature polypeptide), while SCN ELANE mutations are spread over the entire five-exon sequence.[16] Although studies have suggested a relationship between individual ELANE mutations and disease severity (e.g., G185R is associated with a more severe phenotype than the R191Q mutation [21]), a more general genotype-phenotype correlation has not been established.

METHODS

All procedures and consents were approved by the human subjects committees of the investigators’ institutions. Peripheral blood mononuclear cells and granulocytes were purified by Dextran sedimentation and Ficoll/Hypaque centrifugation as previously described. Sperm was isolated by a previously described method.[22] DNA was isolated from leukocytes, buccal swabs, and spermatozoa using the Gentra Puregene Core Kit A or QIAmp DNA Mini Kit (both from Qiagen, Inc., Valencia, CA) according to the manufacturer’s recommended procedures.

PCR amplification of the affected sequence in the ELANE gene was performed with primer sets 8037F(5′-GCA CTC AAG CCA CAT CCA-3′)/8706R (5′-GAT TAG CCC GTT GCA GAC-3′) and 7799F(5′-TTG ATT GGC CCA CCT CAG C-3′)/8706R (primer position numbers refer to the genomic sequence for ELANE, GenBank accession NG_009627). Products of PCR amplification with HotStarTaq DNA Polymerase (Qiagen) were purified from 1% agarose gels using Qiaquick Gel Extraction Kits (Qiagen).

The amplicons were sequenced in the forward and reverse directions using BigDye Terminator V3.1 Cycle Sequencing Kits (Applied Biosystems, Foster City, CA) and a ABI3730×l 96 capillary DNA analyzer (Applied Biosystems). Maximum peak intensities were extracted manually from raw sequencing traces using Sequence Scanner v1.0 software (Applied Biosystems). The fraction of mutant (T) versus wild type (C) allele representation was calculated using the formula T/(C+T)*100% or A/(G+A)*100% for forward or reverse traces, respectively. Averaging of values from forward and reverse traces produced quantitative data that accurately reflected the composition of known mutant and wild type PCR product mixtures. The fraction of mutant allele in sperm DNA was calculated from a calibration curve generated from mixtures containing 0%, 12.5%, 25%, and 50% mutant alleles, with the process repeated in four independent amplification and sequencing runs.

RESULTS

Patients

A previously unreported patient was the product of conception with frozen sperm from the same donor described in our report of five SCN patients in Michigan, all progeny of the same sperm donor [13]. The current patient presented at 12 months of age with severe stomatitis and mouth ulceration. He was subsequently found to have an absolute neutrophil count (ANC) of zero and treated with antibiotics, after which his ANC began to rise. Within the following month he was readmitted for fever and neutropenia, again with stomatitis. Bi-weekly complete blood counts over the following three months showed periods of severe neutropenia (ANC <500/mm3), separated by ANC peaks of 1560/mm3 and 1300/mm3. The pattern included two cycling episodes with 21 days or less between ANC nadirs below 200/mm3. Fig. 1 illustrates two ANC cycles identified prior to G-CSF treatment.

Fig. 1
CN phenotype: ANC cycling from age of 12 months to 12 years, before and during G-CSF treatment. The ordinates show ANC in units of cells × 109/L. Tic marks on the abscissa indicate monthly intervals. Years with no identified cycling and periods ...

A bone marrow examination before G-CSF treatment showed normal cellularity with moderate myeloid hyperplasia and a left-sided myeloid series with myeloid maturation to, but not beyond, the metamyelocyte stage. An anti-neutrophil antibody test showed borderline positive signal for neutrophil-associated IgG in a flow cytometric assay. Due to his severe neutropenia and oral mucositis, the patient began G-CSF treatment and his ANC improved to values above 1000/mm3 within six days. Over the following years, his ANC has continued to demonstrate cycling, with all nadirs (after the first two months of G-CSF treatment) greater than 500/mm3. In 13 cycles monitored during G-CSF therapy, eight have shown periods of 14 days or less (also shown in Figure 1). He currently receives treatment with G-CSF at a dose of 1.2 mcg/kg subcutaneous daily.

Sequencing of the patient’s ELANE gene showed a mutation in the fourth exon, resulting in the amino acid substitution S97L. This mutation is identical to that found to be the common cause of SCN in the previously reported progeny of the sperm donor. The affected amino acid is located on a surface loop, distant from the active site of the protease.

Further investigation has found that the donor has normal peripheral blood counts, and that his wife has borne twins with SCN. All mothers had ELANE genotyping, with no mutations identified. The resultant complete pedigree is shown in Figure 2.

Fig. 2
Pedigree of kindred with CN and SCN phenotypes. Checkered squares (male) and circles (female) represent members with SCN. The filled square represents the patient with a CN phenotype. The square with a vertical dividing line and letter “D” ...

DNA sequence analysis

The missense mutation responsible for the S97L substitution is a C8284T transition [14] in exon 4 of the ELANE gene (GenBank NG_009627). As shown in Fig. 3, sequence analysis of mixtures of DNA from S97L mutant and normal peripheral blood leukocytes showed the expected nearly equal representation of the C and T nucleotides at position 8284 (indicated by the purple box) in the mutant sample, only C in the normal, and a small but detectable T peak in the 25:75 mutant:normal mix. The donor sperm DNA shows a similar ratio of peaks, quantitatively determined to represent 18.0 ± 0.9% (mean±S.D., n=5) mutant sequence.

Fig. 3
DNA sequence chromograms of donor sperm and control DNA samples. The top three lanes represent mixes of 0%, 25%, and 100% mixes of DNA from a normal donor and an SCN patient who is heterozygous for the autosomal dominant S97L mutation. The bottom lane ...

DISCUSSION

This study examined a kindred that includes both a patient with a CN phenotype, as well as seven children with SCN, all of whom share the same paternal haplotype. The cyclic phenotype was established by multiple documented ANCs >500 × 109/L prior to G-CSF therapy, bone marrow demonstrating myeloid maturation to the metamyelocyte stage, and consistent cycling of neutrophil counts, both prior to and on G-CSF therapy. This patient also had a borderline positive anti-neutrophil antibody test, but this finding does not rule out congenital neutropenia.[23] As previously reported for five of the seven the half-siblings [13], those affected with classic SCN had consistent ANC levels < 200 × 109/L prior to G-CSF therapy and bone marrows showing “maturational arrest” at the promyelocyte/myelocyte stage. The current and previously-reported patients all share the S97L ELANE mutation. This specific mutation has been found to be associated with multiple phenotypes,[16] but not in the same family or with a shared haplotype.

The coexistence of CN and SCN phenotypes in this kindred strongly suggests a role for modifying genes in the determination of congenital neutropenia disease phenotypes. Recent studies report that the transcription factors, LEF-1 and Gfi-1 are linked to SCN in mice and humans.[2426] These and other genes associated with neutrophil production may interact with a specific ELANE mutation to determine the phenotype and severity of clinical disease.

Identification of modifying genes may eventually help in the classification of patients with characteristics of both CN and SCN. While CN and SCN are currently classified as two distinct diseases, clinical studies and personal experiences of the authors suggest that CN and SCN represent phenotypes on a disease spectrum. For example, one of the sperm donor’s progeny with SCN has demonstrated (after starting treatment with G-CSF) four consecutive ANC oscillations with magnitudes ranging from 0 to 980 and periods ranging from 16 to 24 days, as did at least one patient on the initial study demonstrating efficacy of G-CSF for treatment of SCN.[27] ANC oscillations may reflect the extent of apoptosis in differentiating myeloid cells, and thus relate to disease phenotype. Further studies of modifying genes are needed to identify these determinants, as well as to create a non-reductionist disease classification based on both genetics and phenotype.[28]

The finding of 18% mutant alleles in the paternal donor’s sperm explains the appearance of congenital neutropenia in eight children from six kindreds. His normal phenotype and lack of detectable mutant DNA in peripheral blood lymphocytes or buccal mucosal epithelial cells indicates that the mosaicism was likely limited to the germ cells, suggesting a new mutation during germ line development and resultant gonadal mosaicism. It is not clear whether the large number of affected offspring, from 20 or fewer fertilizations by the donor’s sperm, represents a statistical anomaly or, less likely, a selective advantage for spermatozoa bearing the mutant allele.

Acknowledgments

We thank Carolyn Padden for technical assistance, Amanda Rawson for editorial assistance, and Julia Keene for preparation of the pedigree. This work was supported by NIH grants R01DK54369 and R24AI049393.

Footnotes

CONFLICT OF INTEREST STATEMENT

None

References

1. Dale DC, Hammond WP. Cyclic neutropenia: a clinical review. Blood Rev. 1988;2:178–185. [PubMed]
2. Palmer SE, Stephens K, Dale DC. Genetics, phenotype, and natural history of autosomal dominant cyclic hematopoiesis. Am J Med Genet. 1996;66:413–422. [PubMed]
3. Boxer LA, Newburger PE. A molecular classification of congenital neutropenia syndromes. Pediatr Blood Cancer. 2007;49:609–614. [PubMed]
4. Donadieu J, Leblanc T, Bader MB, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica. 2005;90:45–53. [PubMed]
5. Freedman MH, Bonilla MA, Fier C, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood. 2000;96:429–436. [PubMed]
6. Hammond WP, Price TH, Souza LM, Dale DC. Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med. 1989;320:1306–1311. [PubMed]
7. Dale DC, Bolyard AA, Aprikyan A. Cyclic neutropenia. Semin Hematol. 2002;39:89–94. [PubMed]
8. Welte K, Boxer LA. Severe chronic neutropenia: pathophysiology and therapy. Semin Hematol. 1997;34:267–278. [PubMed]
9. Wong WY, Williams D, Slovak ML, et al. Terminal acute myelogenous leukemia in a patient with congenital agranulocytosis. Am J Hematol. 1993;43:133–138. [PubMed]
10. Aprikyan AA, Kutyavin T, Stein S, et al. Cellular and molecular abnormalities in severe congenital neutropenia predisposing to leukemia. Exp Hematol. 2003;31:372–381. [PubMed]
11. Ancliff PJ, Gale RE, Liesner R, et al. Mutations in the ELA2 gene encoding neutrophil elastase are present in most patients with sporadic severe congenital neutropenia but only in some patients with the familial form of the disease. Blood. 2001;98:2645–2650. [PubMed]
12. Welte K, Dale D. Pathophysiology and treatment of severe chronic neutropenia. Ann Hematol. 1996;72:158–165. [PubMed]
13. Boxer LA, Stein S, Buckley D, et al. Strong evidence for autosomal dominant inheritance of severe congenital neutropenia associated with ELA2 mutations. J Pediatr. 2006;148:633–636. [PubMed]
14. Dale DC, Person RE, Bolyard AA, et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood. 2000;96:2317–2322. [PubMed]
15. Horwitz M, Benson KF, Person RE, et al. Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. Nat Genet. 1999;23:433–436. [PubMed]
16. Bellanné-Chantelot C, Clauin S, Leblanc T, et al. Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood. 2004;103:4119–4125. [PubMed]
17. Rosenberg PS, Alter BP, Link DC, et al. Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia. Br J Haematol. 2007;140:210–213. [PMC free article] [PubMed]
18. Papadaki HA, Eliopoulos GD. The role of apoptosis in the pathophysiology of chronic neutropenias associated with bone marrow failure. Cell Cycle. 2003;2:447–451. [PubMed]
19. Aprikyan AA, Liles WC, Rodger E, et al. Impaired survival of bone marrow hematopoietic progenitor cells in cyclic neutropenia. Blood. 2001;97:147–153. [PubMed]
20. Kollner I, Sodeik B, Schreek S, et al. Mutations in neutrophil elastase causing congenital neutropenia lead to cytoplasmic protein accumulation and induction of the unfolded protein response. Blood. 2006;108:493–500. [PubMed]
21. Grenda DS, Murakami M, Ghatak J, et al. Mutations of the ELA2 gene found in patients with severe congenital neutropenia induce the unfolded protein response and cellular apoptosis. Blood. 2007;110:4179–4187. [PubMed]
22. Sippel KC, Fraioli RE, Smith GD, et al. Frequency of somatic and germ-line mosaicism in retinoblastoma: implications for genetic counseling. Am J Hum Genet. 1998;62:610–619. [PubMed]
23. Boxer LA, Bolyard AA, Schwinzer B, et al. Antineutrophil antibodies lead to mistaken identity in severe congenital neutropenia. 2005. p. 385.
24. Skokowa J, Fobiwe JP, Dan L, et al. Neutrophil elastase is severely downregulated in severe congenital neutropenia (CN) independent of ELA2 or HAX1 mutations but dependent on LEF-1. 2009. [PubMed]
25. Person RE, Li FQ, Duan Z, et al. Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2. Nat Genet. 2003;34:308–312. [PMC free article] [PubMed]
26. Hochberg JC, Miron PM, Hay BN, et al. Mosaic tetraploidy and transient GFI1 mutation in a patient with severe chronic neutropenia. Pediatr Blood Cancer. 2008;50:630–632. [PubMed]
27. Bonilla MA, Gillio AP, Ruggeiro M, et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med. 1989;320:1574–1580. [PubMed]
28. Loscalzo J, Kohane I, Barabasi AL. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol. 2007;3:124. [PMC free article] [PubMed]